Aran Biomedical Teoranta Announces the Appointment of Todd Blair to the Newly Created Role of VP US Sales & Business Development

June 29, 2020

Aran Biomedical announced the appointment of Mr. Todd Blair as Vice President of Sales and Business Development (US), with effect 1st July 2020.

Aran Biomedical notes this role has been created to meet and manage the growing demand for the companies implantable biomaterial product solutions. Todd will be responsible for leading the Company’s sales and business development activities in the US marketplace with a primary focus on the Orthopaedic, General Surgery and Vascular fields.

Todd Blair joins the company from Heraeus Medical Components where he held the role of Vice President of Corporate Strategy. Todd brings more than 20 years of experience in sales and business development within the life sciences contract manufacturing industry, with a focus on implantable materials and technologies; including Bio-Textiles, Nitinol devices and polymeric components. Todd will support the companies growth plans by identifying new business opportunities and developing and growing those relationships into sustainable and long-term partnerships. In addition, Todd will support internal teams on proposal and product solution development.

“We welcome Todd to Aran Biomedical and are delighted to appoint a candidate of his calibre as Vice President of Sales and Business Development (US),” said Peter Mulrooney CEO, of the company. “The creation of this new position highlights the increasing level of interest Aran Biomedical is seeing in our implantable biomaterial products and services. It also demonstrates the importance of the US market to Aran Biomedical’s growth and expansion plans. We look forward to benefiting from Todd’s vast biomedical textile experience and contact network, to further expand our market presence, particularly for the Orthopaedics, Vascular and General Surgery fields, which are our key growth drivers.”

Hot this week

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."